Symbols / AVTX $16.27 -8.39% Avalo Therapeutics, Inc.
AVTX Chart
About
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 370.77M |
| Enterprise Value | 306.81M | Income | -78.26M | Sales | 59.00K |
| Book/sh | 4.49 | Cash/sh | 4.32 | Dividend Yield | — |
| Payout | 0.00% | Employees | 33 | IPO | — |
| P/E | — | Forward P/E | -5.74 | PEG | — |
| P/S | 6284.21 | P/B | 3.63 | P/C | — |
| EV/EBITDA | -4.23 | EV/Sales | 5200.24 | Quick Ratio | 7.60 |
| Current Ratio | 8.14 | Debt/Eq | 0.51 | LT Debt/Eq | — |
| EPS (ttm) | -5.84 | EPS next Y | -2.83 | EPS Growth | — |
| Revenue Growth | -69.30% | Earnings | 2026-03-23 07:00 | ROA | -34.12% |
| ROE | -72.44% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -334.61% | Profit Margin | 0.00% | Shs Outstand | 22.79M |
| Shs Float | 17.25M | Short Float | 22.19% | Short Ratio | 6.61 |
| Short Interest | — | 52W High | 20.72 | 52W Low | 3.39 |
| Beta | 0.94 | Avg Volume | 579.09K | Volume | 1.09M |
| Target Price | $37.89 | Recom | Strong_buy | Prev Close | $17.76 |
| Price | $16.27 | Change | -8.39% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-06 | init | Citizens | — → Market Outperform | $52 |
| 2026-03-25 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2026-03-24 | reit | BTIG | Buy → Buy | $40 |
| 2026-02-02 | init | Guggenheim | — → Buy | $50 |
| 2026-01-15 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-12-18 | init | Mizuho | — → Outperform | $39 |
| 2025-09-29 | reit | BTIG | Buy → Buy | $40 |
| 2025-09-17 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-08-15 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-03-25 | init | Jefferies | — → Buy | $23 |
| 2025-03-25 | init | Stifel | — → Buy | $36 |
| 2025-03-20 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-28 | init | Piper Sandler | — → Overweight | $48 |
| 2024-12-19 | init | BTIG | — → Buy | $40 |
| 2024-12-17 | init | LUCID CAPITAL MARKETS | — → Buy | $24 |
| 2024-10-24 | init | HC Wainwright & Co. | — → Neutral | — |
| 2024-04-16 | up | Oppenheimer | Perform → Outperform | $35 |
- 65,800-share Form 144 filed by AVTX (NASDAQ: AVTX) - Stock Titan Mon, 06 Apr 2026 20
- Wall Street analysts predict an 113.34% upside in Avalo Therapeutics (AVTX): Here's what you should know - MSN Mon, 06 Apr 2026 07
- Citizens Initiates Coverage on Avalo Therapeutics (AVTX) with Ma - GuruFocus Mon, 06 Apr 2026 11
- Insider Sale: Chief Financial Officer of $AVTX Sells 500 Shares - Quiver Quantitative Fri, 03 Apr 2026 19
- Avalo Therapeutics (NASDAQ:AVTX) Earns Market Outperform Rating from Analysts at Citizens Jmp - MarketBeat Mon, 06 Apr 2026 12
- Avalo Therapeutics (AVTX) CMO Doyle Mittie sells $10,864 in stock - Investing.com Fri, 03 Apr 2026 19
- This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga Mon, 06 Apr 2026 12
- Avalo Therapeutics (AVTX) CMO exercises options, sells 679 pre-planned shares - Stock Titan Fri, 03 Apr 2026 19
- Citizens initiates Avalo Therapeutics stock with outperform rating - Investing.com Mon, 06 Apr 2026 07
- Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $133,807.83 in Stock - MarketBeat Fri, 03 Apr 2026 20
- Avalo Therapeutics (AVTX) CFO executes Rule 10b5-1 stock sale plan - Stock Titan Fri, 03 Apr 2026 19
- Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat Sat, 04 Apr 2026 10
- Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,339 options - Stock Titan Wed, 01 Apr 2026 20
- Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 7,980 Shares - MarketBeat Fri, 03 Apr 2026 20
- Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,370 vested options - Stock Titan Wed, 01 Apr 2026 20
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.06
-86.62%
|
0.44
-77.08%
|
1.92
-89.34%
|
18.05
|
| Operating Revenue |
|
0.06
-86.62%
|
0.44
-77.08%
|
1.92
-89.34%
|
18.05
|
| Cost Of Revenue |
|
0.00
+100.00%
|
-0.37
-128.50%
|
1.28
-62.61%
|
3.43
|
| Reconciled Cost Of Revenue |
|
0.00
+100.00%
|
-0.37
-128.50%
|
1.28
-61.16%
|
3.31
|
| Gross Profit |
|
0.06
-92.69%
|
0.81
+26.09%
|
0.64
-95.62%
|
14.62
|
| Operating Expense |
|
72.98
+75.11%
|
41.68
+73.05%
|
24.08
-53.74%
|
52.06
|
| Research And Development |
|
50.08
+104.95%
|
24.44
+77.29%
|
13.78
-55.97%
|
31.31
|
| Selling General And Administration |
|
22.90
+32.82%
|
17.24
+67.39%
|
10.30
-50.27%
|
20.71
|
| Selling And Marketing Expense |
|
0.47
-40.43%
|
0.79
+2290.91%
|
0.03
-56.58%
|
0.08
|
| General And Administrative Expense |
|
22.43
+36.34%
|
16.45
+60.24%
|
10.27
-50.24%
|
20.64
|
| Salaries And Wages |
|
14.19
+75.49%
|
8.08
+79.76%
|
4.50
-63.90%
|
12.46
|
| Other Gand A |
|
8.24
-1.49%
|
8.37
+45.03%
|
5.77
-29.44%
|
8.18
|
| Total Expenses |
|
72.98
+76.67%
|
41.31
+62.85%
|
25.37
-54.28%
|
55.49
|
| Operating Income |
|
-72.92
-78.43%
|
-40.87
-74.33%
|
-23.44
+37.38%
|
-37.44
|
| Total Operating Income As Reported |
|
-72.92
-6.44%
|
-68.51
-150.49%
|
-27.35
|
—
|
| EBITDA |
|
-72.58
-78.32%
|
-40.70
-74.79%
|
-23.29
+37.53%
|
-37.27
|
| Normalized EBITDA |
|
-63.06
-45.82%
|
-43.25
-131.77%
|
-18.66
+49.94%
|
-37.27
|
| Reconciled Depreciation |
|
0.34
+103.55%
|
0.17
+6.96%
|
0.16
-4.82%
|
0.17
|
| EBIT |
|
-72.92
-78.43%
|
-40.87
-74.33%
|
-23.44
+37.38%
|
-37.44
|
| Total Unusual Items |
|
-9.52
-474.21%
|
2.54
+154.98%
|
-4.63
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-9.52
-474.21%
|
2.54
+154.98%
|
-4.63
|
0.00
|
| Special Income Charges |
|
0.00
+100.00%
|
-36.86
-843.46%
|
-3.91
|
0.00
|
| Other Special Charges |
|
—
|
27.64
|
—
|
—
|
| Impairment Of Capital Assets |
|
—
|
0.00
-100.00%
|
3.91
|
0.00
|
| Restructuring And Mergern Acquisition |
|
0.00
-100.00%
|
9.22
|
0.00
|
—
|
| Net Income |
|
-78.26
-122.78%
|
-35.13
-11.37%
|
-31.54
+24.28%
|
-41.66
|
| Pretax Income |
|
-78.09
-123.03%
|
-35.02
-11.05%
|
-31.53
+24.26%
|
-41.63
|
| Net Non Operating Interest Income Expense |
|
4.35
+31.37%
|
3.31
+196.93%
|
-3.42
+18.06%
|
-4.17
|
| Interest Expense Non Operating |
|
—
|
-3.32
-197.07%
|
3.42
-18.06%
|
4.17
|
| Net Interest Income |
|
4.35
+31.37%
|
3.31
+196.93%
|
-3.42
+18.06%
|
-4.17
|
| Interest Expense |
|
—
|
-3.32
-197.07%
|
3.42
-18.06%
|
4.17
|
| Other Income Expense |
|
-9.52
-474.21%
|
2.54
+154.49%
|
-4.67
-23245.00%
|
-0.02
|
| Other Non Operating Income Expenses |
|
—
|
-0.01
+88.10%
|
-0.04
-110.00%
|
-0.02
|
| Gain On Sale Of Security |
|
-9.52
-124.16%
|
39.41
+5572.92%
|
-0.72
|
—
|
| Tax Provision |
|
0.17
+44.74%
|
0.11
+714.29%
|
0.01
-50.00%
|
0.03
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-2.00
-474.21%
|
0.53
+154.98%
|
-0.97
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-78.26
-122.78%
|
-35.13
-11.37%
|
-31.54
+24.28%
|
-41.66
|
| Net Income From Continuing Operation Net Minority Interest |
|
-78.26
-122.78%
|
-35.13
-11.37%
|
-31.54
+24.28%
|
-41.66
|
| Net Income From Continuing And Discontinued Operation |
|
-78.26
-122.78%
|
-35.13
-11.37%
|
-31.54
+24.28%
|
-41.66
|
| Net Income Continuous Operations |
|
-78.26
-122.78%
|
-35.13
-11.37%
|
-31.54
+24.28%
|
-41.66
|
| Net Income Discontinuous Operations |
|
—
|
—
|
—
|
0.00
|
| Normalized Income |
|
-70.74
-90.47%
|
-37.14
-33.17%
|
-27.89
+33.05%
|
-41.66
|
| Net Income Common Stockholders |
|
-78.26
-122.78%
|
-35.13
-11.37%
|
-31.54
+24.28%
|
-41.66
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
—
|
-20.91
+81.59%
|
-113.58
+89.32%
|
-1,063.20
|
| Basic EPS |
|
—
|
-7.94
+93.01%
|
-113.58
+89.32%
|
-1,063.20
|
| Basic Average Shares |
|
—
|
4.43
+1493.70%
|
0.28
+608.81%
|
0.04
|
| Diluted Average Shares |
|
—
|
7.50
+2599.19%
|
0.28
+608.81%
|
0.04
|
| Diluted NI Availto Com Stockholders |
|
-78.26
-122.78%
|
-35.13
-11.37%
|
-31.54
+24.28%
|
-41.66
|
| Amortization |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Amortization Of Intangibles Income Statement |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Depreciation And Amortization In Income Statement |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Total Other Finance Cost |
|
-4.35
-31.37%
|
-3.31
-196.93%
|
3.42
-18.06%
|
4.17
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
116.46
-22.74%
|
150.73
+618.01%
|
20.99
-37.08%
|
33.37
|
| Current Assets |
|
105.29
-24.19%
|
138.89
+1554.44%
|
8.39
-48.86%
|
16.42
|
| Cash Cash Equivalents And Short Term Investments |
|
98.34
-26.91%
|
134.55
+1714.51%
|
7.42
-43.71%
|
13.17
|
| Cash And Cash Equivalents |
|
15.86
-88.21%
|
134.55
+1714.51%
|
7.42
-43.71%
|
13.17
|
| Other Short Term Investments |
|
82.48
|
0.00
|
—
|
—
|
| Receivables |
|
—
|
0.61
+349.26%
|
0.14
-92.91%
|
1.92
|
| Accounts Receivable |
|
—
|
—
|
—
|
0.00
|
| Other Receivables |
|
—
|
0.61
+349.26%
|
0.14
-92.91%
|
1.92
|
| Inventory |
|
—
|
—
|
0.00
-100.00%
|
0.02
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
0.04
+94.74%
|
0.02
+1800.00%
|
0.00
-93.33%
|
0.01
|
| Other Current Assets |
|
6.91
+59.84%
|
4.33
+413.05%
|
0.84
-34.65%
|
1.29
|
| Total Non Current Assets |
|
11.17
-5.66%
|
11.84
-6.00%
|
12.60
-25.68%
|
16.95
|
| Net PPE |
|
0.46
-61.95%
|
1.21
-38.47%
|
1.97
-18.50%
|
2.41
|
| Gross PPE |
|
0.71
-62.85%
|
1.92
-23.45%
|
2.51
-11.26%
|
2.83
|
| Accumulated Depreciation |
|
-0.25
+64.37%
|
-0.71
-31.00%
|
-0.54
-30.92%
|
-0.41
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.14
-51.06%
|
0.28
+0.00%
|
0.28
-16.07%
|
0.34
|
| Other Properties |
|
—
|
—
|
1.33
-24.06%
|
1.75
|
| Leases |
|
0.57
-64.87%
|
1.64
-26.43%
|
2.23
+201.08%
|
0.74
|
| Goodwill And Other Intangible Assets |
|
10.50
+0.00%
|
10.50
+0.00%
|
10.50
-27.11%
|
14.41
|
| Goodwill |
|
10.50
+0.00%
|
10.50
+0.00%
|
10.50
-27.11%
|
14.41
|
| Other Intangible Assets |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
0.21
+60.31%
|
0.13
+0.00%
|
0.13
+0.00%
|
0.13
|
| Total Liabilities Net Minority Interest |
|
33.41
+88.75%
|
17.70
+29.30%
|
13.69
-69.09%
|
44.28
|
| Current Liabilities |
|
12.94
+85.92%
|
6.96
+50.71%
|
4.62
-79.12%
|
22.11
|
| Payables And Accrued Expenses |
|
8.42
+167.26%
|
3.15
-10.05%
|
3.50
-71.73%
|
12.38
|
| Payables |
|
0.46
-23.93%
|
0.61
+36.77%
|
0.45
-86.84%
|
3.39
|
| Accounts Payable |
|
0.14
-51.59%
|
0.28
-36.55%
|
0.45
-84.52%
|
2.88
|
| Other Payable |
|
0.33
+0.00%
|
0.33
|
—
|
0.51
|
| Current Accrued Expenses |
|
7.95
+213.19%
|
2.54
-16.89%
|
3.06
-66.04%
|
8.99
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
4.13
+43.32%
|
2.88
+397.07%
|
0.58
-78.51%
|
2.70
|
| Total Tax Payable |
|
—
|
—
|
—
|
—
|
| Income Tax Payable |
|
—
|
—
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.39
-30.99%
|
0.57
+5.77%
|
0.54
-91.69%
|
6.46
|
| Current Debt |
|
—
|
—
|
—
|
5.93
|
| Other Current Borrowings |
|
—
|
—
|
—
|
5.93
|
| Current Capital Lease Obligation |
|
0.39
-30.99%
|
0.57
+5.77%
|
0.54
+0.94%
|
0.53
|
| Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.09
|
| Current Deferred Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.09
|
| Other Current Liabilities |
|
—
|
0.36
|
—
|
0.48
|
| Total Non Current Liabilities Net Minority Interest |
|
20.47
+90.59%
|
10.74
+18.40%
|
9.07
-59.08%
|
22.17
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
13.49
|
| Long Term Debt |
|
—
|
—
|
—
|
13.49
|
| Non Current Deferred Liabilities |
|
0.43
+60.74%
|
0.27
+74.19%
|
0.15
+9.93%
|
0.14
|
| Non Current Deferred Taxes Liabilities |
|
0.43
+60.74%
|
0.27
+74.19%
|
0.15
+9.93%
|
0.14
|
| Other Non Current Liabilities |
|
2.04
-13.40%
|
2.35
-30.18%
|
3.37
-9.30%
|
3.71
|
| Preferred Securities Outside Stock Equity |
|
0.00
|
0.00
|
0.00
|
—
|
| Stockholders Equity |
|
83.05
-37.57%
|
133.03
+1721.36%
|
7.30
+166.92%
|
-10.91
|
| Common Stock Equity |
|
83.05
-37.57%
|
133.03
+1721.36%
|
7.30
+166.92%
|
-10.91
|
| Capital Stock |
|
0.02
+80.00%
|
0.01
+900.00%
|
0.00
|
0.00
|
| Common Stock |
|
0.02
+80.00%
|
0.01
+900.00%
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
—
|
| Share Issued |
|
18.51
+76.78%
|
10.47
+1206.14%
|
0.80
+1940.43%
|
0.04
|
| Ordinary Shares Number |
|
18.51
+76.78%
|
10.47
+1206.14%
|
0.80
+1940.43%
|
0.04
|
| Additional Paid In Capital |
|
531.49
+5.60%
|
503.29
+46.97%
|
342.44
+16.91%
|
292.91
|
| Retained Earnings |
|
-448.52
-21.14%
|
-370.26
-10.48%
|
-335.13
-10.31%
|
-303.82
|
| Gains Losses Not Affecting Retained Earnings |
|
0.07
|
0.00
|
—
|
—
|
| Other Equity Adjustments |
|
0.07
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
83.05
-37.57%
|
133.03
+1721.36%
|
7.30
+166.92%
|
-10.91
|
| Total Capitalization |
|
83.05
-37.57%
|
133.03
+1721.36%
|
7.30
+184.09%
|
2.57
|
| Working Capital |
|
92.35
-30.00%
|
131.93
+3392.98%
|
3.78
+166.29%
|
-5.70
|
| Invested Capital |
|
83.05
-37.57%
|
133.03
+1721.36%
|
7.30
-14.08%
|
8.50
|
| Total Debt |
|
0.39
-30.99%
|
0.57
+5.77%
|
0.54
-97.31%
|
19.95
|
| Net Debt |
|
—
|
—
|
—
|
6.24
|
| Capital Lease Obligations |
|
0.39
-30.99%
|
0.57
+5.77%
|
0.54
+0.94%
|
0.53
|
| Net Tangible Assets |
|
72.55
-40.79%
|
122.53
+3931.46%
|
-3.20
+87.37%
|
-25.32
|
| Tangible Book Value |
|
72.55
-40.79%
|
122.53
+3931.46%
|
-3.20
+87.37%
|
-25.32
|
| Derivative Product Liabilities |
|
18.00
+121.67%
|
8.12
+46.31%
|
5.55
+14.91%
|
4.83
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-51.46
-4.90%
|
-49.06
-59.90%
|
-30.68
-14.69%
|
-26.75
|
| Cash Flow From Continuing Operating Activities |
|
-51.46
-4.90%
|
-49.06
-59.90%
|
-30.68
-14.69%
|
-26.75
|
| Net Income From Continuing Operations |
|
-78.26
-122.78%
|
-35.13
-11.37%
|
-31.54
+24.28%
|
-41.66
|
| Depreciation Amortization Depletion |
|
0.34
+103.55%
|
0.17
+6.96%
|
0.16
-4.82%
|
0.17
|
| Depreciation And Amortization |
|
0.34
+103.55%
|
0.17
+6.96%
|
0.16
-4.82%
|
0.17
|
| Other Non Cash Items |
|
-0.69
-102.87%
|
24.05
+1215.70%
|
1.83
+31.61%
|
1.39
|
| Stock Based Compensation |
|
13.62
+132.76%
|
5.85
+68.31%
|
3.48
-53.97%
|
7.55
|
| Provisionand Write Offof Assets |
|
—
|
—
|
—
|
1.00
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
3.91
|
0.00
|
| Deferred Tax |
|
0.17
+44.74%
|
0.11
+714.29%
|
0.01
-50.00%
|
0.03
|
| Deferred Income Tax |
|
0.17
+44.74%
|
0.11
+714.29%
|
0.01
-50.00%
|
0.03
|
| Operating Gains Losses |
|
9.52
+124.16%
|
-39.41
-5572.92%
|
0.72
-87.65%
|
5.83
|
| Gain Loss On Investment Securities |
|
9.52
+124.16%
|
-39.41
-5572.92%
|
0.72
-85.09%
|
4.83
|
| Change In Working Capital |
|
3.84
+181.58%
|
-4.71
+49.05%
|
-9.24
-15300.00%
|
-0.06
|
| Change In Receivables |
|
0.00
+100.00%
|
-0.47
-126.64%
|
1.78
-38.09%
|
2.88
|
| Changes In Account Receivables |
|
—
|
—
|
0.00
-100.00%
|
1.06
|
| Change In Inventory |
|
—
|
0.00
-100.00%
|
0.02
+11.11%
|
0.02
|
| Change In Prepaid Assets |
|
-2.59
+9.86%
|
-2.87
-742.28%
|
0.45
-58.69%
|
1.08
|
| Change In Payables And Accrued Expense |
|
6.52
+611.46%
|
-1.27
+88.91%
|
-11.48
-178.81%
|
-4.12
|
| Change In Accrued Expense |
|
6.66
+699.64%
|
-1.11
+87.72%
|
-9.05
-149.12%
|
-3.63
|
| Change In Payable |
|
-0.15
+10.43%
|
-0.16
+93.31%
|
-2.44
-400.21%
|
-0.49
|
| Change In Account Payable |
|
-0.15
+10.43%
|
-0.16
+93.31%
|
-2.44
-400.21%
|
-0.49
|
| Change In Other Working Capital |
|
—
|
—
|
0.07
-20.45%
|
0.09
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
0.00
|
| Change In Other Current Liabilities |
|
-0.09
+1.14%
|
-0.09
-15.79%
|
-0.08
-744.44%
|
-0.01
|
| Investing Cash Flow |
|
-81.72
-23055.06%
|
0.36
+367.67%
|
-0.13
-40.00%
|
-0.10
|
| Cash Flow From Continuing Investing Activities |
|
-81.72
-23055.06%
|
0.36
+367.67%
|
-0.13
-40.00%
|
-0.10
|
| Net PPE Purchase And Sale |
|
—
|
0.00
-100.00%
|
0.03
+126.32%
|
-0.10
|
| Purchase Of PPE |
|
—
|
—
|
0.00
+100.00%
|
-0.10
|
| Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.03
|
0.00
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.10
|
| Net Investment Purchase And Sale |
|
-81.72
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-113.72
|
0.00
|
—
|
—
|
| Sale Of Investment |
|
32.00
|
0.00
|
—
|
—
|
| Net Business Purchase And Sale |
|
0.00
-100.00%
|
0.36
|
0.00
|
—
|
| Purchase Of Business |
|
—
|
—
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
-0.16
|
—
|
| Financing Cash Flow |
|
14.59
-91.70%
|
175.85
+602.22%
|
25.04
+270.37%
|
-14.70
|
| Cash Flow From Continuing Financing Activities |
|
14.59
-91.70%
|
175.85
+602.22%
|
25.04
+270.37%
|
-14.70
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
+100.00%
|
-21.24
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-21.24
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-21.24
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-21.24
|
0.00
|
| Net Common Stock Issuance |
|
14.76
-87.23%
|
115.62
+150.17%
|
46.22
+412.88%
|
-14.77
|
| Common Stock Payments |
|
—
|
—
|
—
|
-14.81
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
-14.81
|
| Proceeds From Stock Option Exercised |
|
0.80
-98.85%
|
69.44
+103546.27%
|
0.07
-8.22%
|
0.07
|
| Net Other Financing Charges |
|
-0.97
+89.46%
|
-9.22
|
—
|
—
|
| Changes In Cash |
|
-118.59
-193.27%
|
127.15
+2303.24%
|
-5.77
+86.11%
|
-41.55
|
| Beginning Cash Position |
|
134.70
+1684.76%
|
7.55
-43.33%
|
13.32
-75.72%
|
54.86
|
| End Cash Position |
|
16.11
-88.04%
|
134.70
+1684.76%
|
7.55
-43.33%
|
13.32
|
| Free Cash Flow |
|
-51.46
-4.90%
|
-49.06
-59.90%
|
-30.68
-14.28%
|
-26.85
|
| Interest Paid Supplemental Data |
|
—
|
0.00
-100.00%
|
1.93
-34.32%
|
2.93
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Change In Income Tax Payable |
|
—
|
—
|
—
|
0.00
|
| Change In Tax Payable |
|
—
|
—
|
—
|
0.00
|
| Common Stock Issuance |
|
14.76
-87.23%
|
115.62
+150.17%
|
46.22
+135838.24%
|
0.03
|
| Earnings Losses From Equity Investments |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
14.76
-87.23%
|
115.62
+150.17%
|
46.22
+135838.24%
|
0.03
|
| Sale Of Business |
|
0.00
-100.00%
|
0.36
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-01 View
- 42026-04-01 View
- 42026-03-31 View
- 42026-03-31 View
- 42026-03-31 View
- 42026-03-31 View
- 42026-03-31 View
- 42026-03-31 View
- 42026-03-31 View
- 8-K2026-03-27 View
- 10-K2026-03-23 View
- 8-K2026-03-23 View
- 42026-03-18 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
- 42026-03-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|